 WALTHAM, Mass.--BUSINESS WIRE--Deciphera Pharmaceuticals, Inc. NASDAQ: DCPH, a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion recommending the approval of QINLOCK ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor GIST who have receiv 